GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Asset Impairment Charge

EBACU (European Biotech Acquisition) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Asset Impairment Charge?

European Biotech Acquisition's Asset Impairment Charge for the three months ended in Dec. 2022 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

European Biotech Acquisition Asset Impairment Charge Historical Data

The historical data trend for European Biotech Acquisition's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Asset Impairment Charge Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Asset Impairment Charge
- -

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

European Biotech Acquisition Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

European Biotech Acquisition Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Asset Impairment Charge
Comparable Companies
CNTQ LION MEOA SCMA LATG NBST CCTS FRBN NMMC DMAQ GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
Website
https://www.lspvc.com
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV